Progress in the Treatment of IVIG-Resistant Kawasaki Disease with Infliximab
- 1 January 2020
- journal article
- Published by Hans Publishers in Asian Case Reports in Pediatrics
- Vol. 08 (02), 18-22
- https://doi.org/10.12677/acrp.2020.82004
Abstract
川崎病(Kawasaki disease, KD)是一种以全身性血管炎为特征的急性自限性疾病,病因尚不清楚,静脉注射丙种球蛋白(intravenous immunoglobulin, IVIG)联合阿司匹林治疗可缓解川崎病的炎症反应,但仍有部分患者对治疗无反应,本文主要针对英夫利昔单抗在IVIG无反应型川崎病中的应用进行综述。 Kawasaki disease is an acute self-limited disease characterized by systemic vasculitis; etiology is unclear; intravenous immunoglobulin and aspirin therapy can alleviate the inflammation of Kawasaki disease, but there are still some patients do not respond to treatment. This review focuses on the application of infliximab in IVIG reactive Kawasaki disease.This publication has 25 references indexed in Scilit:
- Efficacy and safety of plasma exchange for Kawasaki disease with coronary artery dilatationRenal Replacement Therapy, 2017
- Adjunctive therapies for Kawasaki diseaseJournal of Infection, 2016
- Kawasaki DiseaseJournal of Invasive Cardiology, 2016
- Recent Advances in Kawasaki DiseaseYonsei Medical Journal, 2016
- The epidemiology of Kawasaki disease: a global updateArchives of Disease in Childhood, 2015
- Update on etio and immunopathogenesis of Kawasaki diseaseCurrent Opinion in Rheumatology, 2014
- Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki diseaseArthritis & Rheumatism, 2013
- Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki diseaseCytokine, 2012
- Predictive risk factors for coronary artery abnormalities in Kawasaki diseaseEuropean Journal of Pediatrics, 2006
- Initial Intravenous Gammaglobulin Treatment Failure in Kawasaki DiseasePEDIATRICS, 2000